Driehaus Capital Management LLC Ovid Therapeutics Inc. Transaction History

Driehaus Capital Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$1.88 - $2.85 $325,110 - $492,853	-172,931 Reduced 12.09%	1,257,337 $3.24 Million
Q3 2022 Nov 14, 2022	BUY	$1.85 - $2.26 $160,844 - $196,491	86,943 Added 6.47%	1,430,268 $2.63 Million
Q2 2022 Aug 15, 2022	BUY	$1.69 - $3.31 $1.66 Million - $3.25 Million	983,349 Added 273.17%	1,343,325 $2.89 Million
Q1 2022 May 16, 2022	BUY	$2.65 - $3.49 $953,936 - $1.26 Million	359,976 New	359,976 $1.13 Million
Q4 2018 Feb 14, 2019	SELL	$2.42 - $6.6 $510,878 - $1.39 Million	-211,107 Closed	0 $0

Q3 2018 Nov 14, 2018	SELL	$5.6 - $11.0 $415,475 - $816,112	-74,192 Reduced 26.0%	211,107 $1.2 Million
Q2 2018 Aug 14, 2018	BUY	$6.16 - $10.14 $8,506 - $14,003	1,381 Added 0.49%	285,299 $2.23 Million
Q1 2018 May 15, 2018	BUY	$6.53 - $9.82 $79,803 - $120,010	12,221 Added 4.5%	283,918 $2.01 Million
Q4 2017 Feb 14, 2018	BUY	$6.12 - $12.31 $41,616 - $83,708	6,800 Added 2.57%	271,697 $2.68 Million
Q3 2017 Nov 14, 2017	BUY	$5.32 - $9.77 $1.41 Million - $2.59 Million	264,897	264,897 $2.27 Million

43.2M

5.9K

300

Ticker OVID
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,419,400
Market Cap $52.8M
Description
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment o...

Get notified when there are updates to the investment portfolio of Driehaus Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Driehaus Capital Management LLC with notifications on news.